CD4+CD25+ regulatory T cells (Treg cells) control immune responsiveness to a large variety of antigens. The isolation and therapeutic manipulation of Treg cells requires the use of reliable surface receptors that are selectively up-regulated in Treg cells. On the basis of global gene expression studies, we identified neuropilin-1 (Nrp1) as a specific surface marker for CD4+CD25+ Treg cells. Nrp1, a receptor involved in axon guidance, angiogenesis, and the activation of T cells, is constitutively expressed on the surface of CD4+CD25+ Treg cells independently of their activation status. In contrast, Nrp1 expression is down-regulated in naive CD4+CD25- T cells after TCR stimulation. Furthermore, CD4+Nrp1(high) T cells express high levels of Foxp3 and suppress CD4+CD25- T cells. Thus, Nrp1 constitutes a useful surface marker to distinguish Treg cells from both naive and recently activated CD4+CD25+ non-regulatory T cells.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200324799DOI Listing

Publication Analysis

Top Keywords

treg cells
24
cells
13
surface marker
12
regulatory cells
8
cd4+cd25+ treg
8
cells nrp1
8
cd4+cd25- cells
8
treg
6
neuropilin-1 surface
4
marker regulatory
4

Similar Publications

Estrogen sulfotransferase (SULT1E1), a member of the sulfotransferase family (SULTs), is the enzyme with the strongest affinity for estrogen. Despite significant associations between SULT1E1 and the progression and prognosis of a range of diseases, its functional role and potential mechanisms in lung adenocarcinoma (LUAD) remain unclear. The objective of this study was to examine the potential of SULT1E1 as a biomarker for LUAD.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) are the first line of treatment for many solid tumors including melanoma. PD-1 blockade enhances the effector functions of melanoma-infiltrating CD8 T cells, leading to durable tumor remissions. However, 55% of patients with melanoma do not respond to treatment.

View Article and Find Full Text PDF

Potential regulation of artesunate on bone metabolism through suppressing inflammatory infiltration in type 2 diabetes mellitus.

Immunopharmacol Immunotoxicol

January 2025

Department of Oral & Maxillofacial Surgery, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, China.

Objective: Osteoimmunology is an emerging field that explores the interplay between bone and the immune system. The immune system plays a critical role in the pathogenesis of diabetes and significantly affects bone homeostasis. Artesunate, a first-line treatment for malaria, is known for its low toxicity and multifunctional properties.

View Article and Find Full Text PDF

FoxP3 T-regulatory (Treg) lymphocytes and cytokine production by cells from the stromal vascular fraction (SVF) of epicardial (EAT) and thymus (TAT) adipose tissue of 42 patients with chronic coronary heart disease (CHD) were studied. In the SVF of TAT in patients with Gensini Score (GS)≥74 (the most severe atherosclerosis), the production of IL-1β, TNF, IL-4, and IFNγ was higher, while FoxP3 translocation into the nucleus was lower than in patients with GS<74. The GS index directly correlated with the production of IL-4, IL-1β, and TNF by cells of the SVF of TAT, and inversely - with the production of TNF, IL-17, and IL-10 by cells of the SVF of EAT.

View Article and Find Full Text PDF

Dose effect of corticosteroids on peripheral lymphocyte profiles in patients with systemic lupus erythematosus.

Clin Rheumatol

January 2025

Department of Rheumatology and Immunology, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, China.

Objective: To investigate the dose effect of methylprednisolone (MP) on peripheral lymphocyte profiles in patients with systemic lupus erythematosus (SLE). This study investigated the impact of varied MP doses on peripheral lymphocyte subtypes in SLE patients.

Methods: We conducted a prospective study involving 51 SLE patients, categorized into four groups (40 mg/day, 80 mg/day, 500 mg/day, and 1000 mg/day) based on the administered MP dosage during hospitalization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!